Navigation Links
Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
Date:7/17/2012

SAN DIEGO, July 17, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the appointment of Daniel Ripley as Head of Corporate Development, effective immediately.  Mr. Ripley will lead licensing, partnering initiatives, intellectual property analysis and act as the internal coordinator of the emricasan commercialization strategy development.

"Dan brings experience in both in-licensing and out-licensing of commercial products as well as extensive experience in partnering early-to-late stage products", said Steven J. Mento, Ph.D., President and CEO. "His varied experience in drug development transactions will be particularly important as we move forward with the development of emricasan, our first-in-class caspase inhibitor, into Phase 3 clinical trials for acute liver failure and liver fibrosis, and the related coordination of its commercialization activities".

We also want to continue our strong track record of success with collaborative drug discovery partnerships with large pharmaceutical companies, expanding the development of emricasan for disease targets other than liver disease as well as monitoring our collaboration with Abbott Laboratories in cancer," continued Dr. Mento.  "In addition, we have a leadership position in intellectual property related to programmed cell death (apoptosis) including ongoing relationships with thought leaders in the field of apoptosis and in our targeted disease areas. We possess an extensive patent portfolio comprised of over 130 issued patents including patents covering composition of matter on validated drug targets and new chemical entities (NCEs) addressing those targets, as well as broad fields of use, drug-screening assays, diagnostics and antibodies.  Dan will be involved in seeking business opportunities in each of these areas".

For more than a decade, Mr. Ripley has been involved with emerging growth life science companies in the development and execution of strategic business transactions.  His experiences include M&A, technology licenses and alliance transactions with pharmaceutical companies.  Mr. Ripley was instrumental in business negotiations at Kalypsys, Inc. and Isis Pharmaceuticals where he closed over $350 million in transactions.

Mr. Ripley earned his M.B.A. with an emphasis in Finance and a B.S. in Microbiology both from San Diego State University.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer.   Conatus acquired the Idun subsidiary from Pfizer in 2010.  For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... Florida , January 19, 2017 ... Trump administration appears serious about reducing the FDA,s ... and innovation in the medical drug industry, many ... ahead with new clinical trials and development of ... companies forging ahead with recent developments include:  Moleculin ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between ... they no longer use or need, from clothes to couches to dressers and bicycles. ... and take them to the nearest Goodwill donation center through February 28th. , ...
(Date:1/20/2017)... Miami, Florida (PRWEB) , ... January 20, 2017 , ... ... in head lice cases in families with school-aged children since the holiday season. ... spend the holidays with their families, sharing hugs and taking photos, which is the ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... its sugar-free alternative VW+ 002. The drinks have been produced in collaboration with ... to perform during your workout. , After a successful launch in Sweden last ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: an ... of published author, Keith C. A. Tucker, son of Minister Delores Pinnock and a ... by Reverend Mark Hardy , “While sitting up in bed, I felt a pounding ...
Breaking Medicine News(10 mins):